Segall Bryant & Hamill LLC Purchases 41,739 Shares of Myriad Genetics, Inc. (NASDAQ:MYGN)

Segall Bryant & Hamill LLC boosted its position in Myriad Genetics, Inc. (NASDAQ:MYGN) by 137.4% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 72,117 shares of the company’s stock after buying an additional 41,739 shares during the quarter. Segall Bryant & Hamill LLC owned approximately 0.08% of Myriad Genetics worth $989,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds have also recently made changes to their positions in the company. Point72 Hong Kong Ltd purchased a new stake in Myriad Genetics in the 3rd quarter worth about $32,000. KBC Group NV increased its stake in shares of Myriad Genetics by 132.8% in the fourth quarter. KBC Group NV now owns 5,845 shares of the company’s stock worth $80,000 after purchasing an additional 3,334 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. raised its position in shares of Myriad Genetics by 43.8% in the third quarter. Point72 Asia Singapore Pte. Ltd. now owns 4,833 shares of the company’s stock valued at $132,000 after purchasing an additional 1,471 shares during the period. Quantbot Technologies LP purchased a new stake in shares of Myriad Genetics during the 3rd quarter valued at approximately $153,000. Finally, Inspire Advisors LLC boosted its holdings in Myriad Genetics by 48.1% in the 4th quarter. Inspire Advisors LLC now owns 11,226 shares of the company’s stock worth $154,000 after buying an additional 3,644 shares during the period. 99.02% of the stock is currently owned by institutional investors.

Myriad Genetics Stock Performance

NASDAQ MYGN opened at $8.88 on Friday. Myriad Genetics, Inc. has a 52-week low of $8.70 and a 52-week high of $29.30. The company has a fifty day moving average of $11.76 and a 200-day moving average of $16.57. The company has a market capitalization of $810.82 million, a P/E ratio of -6.83 and a beta of 1.79. The company has a debt-to-equity ratio of 0.05, a quick ratio of 1.73 and a current ratio of 1.90.

Myriad Genetics (NASDAQ:MYGN) last issued its quarterly earnings results on Tuesday, February 25th. The company reported ($0.09) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.03 by ($0.12). The firm had revenue of $210.60 million for the quarter, compared to the consensus estimate of $210.35 million. Myriad Genetics had a negative return on equity of 4.51% and a negative net margin of 14.09%. During the same period last year, the firm earned ($0.12) EPS. As a group, equities research analysts predict that Myriad Genetics, Inc. will post -0.3 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several research firms have issued reports on MYGN. Leerink Partners downgraded Myriad Genetics from an “outperform” rating to a “market perform” rating and dropped their target price for the stock from $30.00 to $21.00 in a research report on Monday, December 9th. Leerink Partnrs cut Myriad Genetics from a “strong-buy” rating to a “hold” rating in a report on Monday, December 9th. Raymond James reaffirmed an “outperform” rating and set a $19.00 target price (down previously from $27.00) on shares of Myriad Genetics in a report on Tuesday, February 25th. Bank of America lowered their price target on shares of Myriad Genetics from $13.00 to $11.00 and set an “underperform” rating on the stock in a report on Monday, March 3rd. Finally, The Goldman Sachs Group reduced their price objective on shares of Myriad Genetics from $29.00 to $18.00 and set a “buy” rating for the company in a research note on Tuesday, January 28th. Three equities research analysts have rated the stock with a sell rating, six have assigned a hold rating and seven have issued a buy rating to the company. According to data from MarketBeat, Myriad Genetics has a consensus rating of “Hold” and a consensus price target of $21.89.

Myriad Genetics Company Profile

Myriad Genetics, Inc, a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and pharmacogenomics. It also provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer.